The Chemours Stock Forecast, Price & News

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for The Chemours in the last twelve months. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" The Chemours stock.
View analyst ratings for The Chemours or view top-rated stocks.

Wall Street analysts have given The Chemours a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but The Chemours wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

The Chemours is scheduled to release its next quarterly earnings announcement on Tuesday, November 2nd 2021.
View our earnings forecast for The Chemours.

The Chemours Company (NYSE:CC) posted its earnings results on Thursday, July, 29th. The specialty chemicals company reported $1.20 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.89 by $0.31. The specialty chemicals company earned $1.66 billion during the quarter, compared to analyst estimates of $1.51 billion. The Chemours had a trailing twelve-month return on equity of 61.31% and a net margin of 4.57%.
View The Chemours' earnings history.

The Chemours' stock was trading at $10.66 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CC stock has increased by 191.9% and is now trading at $31.12.
View which stocks have been most impacted by COVID-19.

The Chemours declared a quarterly dividend on Wednesday, July 28th. Shareholders of record on Monday, August 16th will be given a dividend of $0.25 per share on Wednesday, September 15th. This represents a $1.00 annualized dividend and a yield of 3.21%. The ex-dividend date of this dividend is Friday, August 13th.
View The Chemours' dividend history.

The Chemours pays an annual dividend of $1.00 per share and currently has a dividend yield of 3.23%. The dividend payout ratio of The Chemours is 50.51%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, The Chemours will have a dividend payout ratio of 25.19% next year. This indicates that The Chemours will be able to sustain or increase its dividend.
View The Chemours' dividend history.

The Chemours issued an update on its FY 2021 earnings guidance on Thursday, August, 5th. The company provided earnings per share guidance of $3.560-$3.560 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.560. The company issued revenue guidance of -.

9 Wall Street analysts have issued 12-month price targets for The Chemours' stock. Their forecasts range from $28.00 to $48.00. On average, they expect The Chemours' stock price to reach $37.78 in the next twelve months. This suggests a possible upside of 21.4% from the stock's current price.
View analysts' price targets for The Chemours or view top-rated stocks among Wall Street analysts.

106 employees have rated The Chemours CEO Mark Vergnano on Glassdoor.com. Mark Vergnano has an approval rating of 85% among The Chemours' employees.

Some companies that are related to The Chemours include Asahi Kasei (AHKSY), FMC (FMC), Olin (OLN), Johnson Matthey (JMPLY), Huntsman (HUN), Ashland Global (ASH), W. R. Grace & Co. (GRA), Balchem (BCPC), Livent (LTHM), Univar Solutions (UNVR), Showa Denko K.K. (SHWDY), Kuraray (KURRY), Ingevity (NGVT), Innospec (IOSP) and GCP Applied Technologies (GCP).
View all of CC's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other The Chemours investors own include AT&T (T), Pfizer (PFE), DuPont de Nemours (DD), NVIDIA (NVDA), Cisco Systems (CSCO), Micron Technology (MU), Intel (INTC), AbbVie (ABBV), CVS Health (CVS) and Energy Transfer (ET).

The Chemours trades on the New York Stock Exchange (NYSE) under the ticker symbol "CC."

The Chemours' stock is owned by a number of institutional and retail investors. Top institutional shareholders include FMR LLC (12.13%), Vanguard Group Inc. (9.67%), BlackRock Inc. (8.34%), State Street Corp (2.62%), Allianz Asset Management GmbH (2.57%) and LSV Asset Management (2.31%). Company insiders that own The Chemours stock include Alvenia Scarborough, David C Shelton, Denise Dignam, E Bryan Snell, Edwin C Sparks, Mark Newman, Mark P Vergnano, Matthew S Abbott, Richard H Brown and Sameer Ralhan.
View institutional ownership trends for The Chemours.

CC stock was sold by a variety of institutional investors in the last quarter, including Sandler Capital Management, AQR Capital Management LLC, BlackRock Inc., Wells Fargo & Company MN, Miller Value Partners LLC, Panagora Asset Management Inc., Russell Investments Group Ltd., and Citadel Advisors LLC. Company insiders that have sold The Chemours company stock in the last year include Alvenia Scarborough, David C Shelton, Denise Dignam, Edwin C Sparks, Mark Newman, Mark P Vergnano, Matthew S Abbott, and Sameer Ralhan.
View insider buying and selling activity for The Chemours or view top insider-selling stocks.

CC stock was bought by a variety of institutional investors in the last quarter, including American Century Companies Inc., Allianz Asset Management GmbH, Morgan Stanley, Morgan Stanley, FMR LLC, First Trust Advisors LP, Mackenzie Financial Corp, and State Street Corp. Company insiders that have bought The Chemours stock in the last two years include E Bryan Snell, Mark Newman, and Richard H Brown.
View insider buying and selling activity for The Chemours or or view top insider-buying stocks.

Shares of CC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CC stock can currently be purchased for approximately $31.12.

The Chemours has a market capitalization of $5.14 billion and generates $4.97 billion in revenue each year. The specialty chemicals company earns $219 million in net income (profit) each year or $1.98 on an earnings per share basis.

The Chemours employs 6,500 workers across the globe.

The official website for The Chemours is www.chemours.com.

The Chemours is headquartered at 1007 MARKET STREET, WILMINGTON DE, 19801.

The Chemours' mailing address is 1007 MARKET STREET, WILMINGTON DE, 19801. The specialty chemicals company can be reached via phone at (302) 773-1000 or via email at [email protected]